# NCT05633654 (NCT05633654)

> Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05633654
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Gilead Sciences
- Conditions: Triple Negative Breast Cancer
- Interventions: Sacituzumab govitecan-hziy (SG); Pembrolizumab; Capecitabine
- Enrollment: 1514
- Primary outcome: Invasive Disease-free Survival (iDFS)

## Indexed commentary on NCT05633654 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05633654